Esokia laughs
–
Mission: To study the role of the X and Z genes in the aggressiveness and resistance to treatment of glioblastoma
Reception establishmentl: Team 8 GlioME (Gliomagenesis and Microenvironment) – Institute of Neurophysiopathology – Faculty of Medicine Timone – MARSEILLE
Site web : https://inp.univ-amu.fr/en/teams/gliome-gliomagenesis-and-microenvironment
concerned public : Engineer
This position is to be filled from January 1, 2022 – Compensation according to the Aix-Marseille University grids.
context
Within the Institute of Neurophysiopathology in Marseille (UMR CNRS / AMU 7051), our GlioME team (Gliomagenesis and MicroEnvironment) conducts fundamental and preclinical research on human gliomas. Gliomas are the most common intracranial tumors in humans. Despite optimal surgical resection followed by chemotherapy and radiotherapy, the median survival of patients with glioblastoma (GBM, the most common and malignant form of glioma) remains approximately 12 to 15 months. Our team therefore sets out to study the biology of GBMs (cell composition, tumor growth, interactions with the microenvironment) in order to identify new targets and evaluate promising therapeutic strategies using cutting-edge methods and technologies. (cultures of cancerous stem cells in 2D and 3D, murine models, two-photon microscopy…).
Project
For several years, we have been interested in the molecular profile of recurrent glioblastomas after radiotherapy and chemotherapy in order to highlight the factors responsible for the inevitable relapse of these tumors. We have demonstrated a modification of the angiogenic process of GBM at initial diagnosis, in favor of vasculogenesis at relapse (Tabouret et al.). This phenomenon could be involved in the therapeutic escape of these tumors.
Recently, we have identified by transcriptomic analyzes, two genes, X and Z, significantly overexpressed at the time of therapeutic escape.
Our objective is now 1) to study the impact of the modulation of the expression of these genes on tumorigenicity in in vitro and ex vivo preclinical models of glioblastoma by Sh-RNA type approaches and 2) to develop to term of therapeutic approaches targeting these genes using a secondarily vectorized Si-RNA technique.
This study will use in particular an ex vivo model of tumoroids that we are developing in the laboratory in collaboration with the neurosurgeons of the APHM.
Main activities :
– Cultivate stem cell lines (spheroids) and conventional
– Analyze cell proliferation, cell cycle, apoptosis
– Extract proteins and perform western blots
– Extract RNA and perform RTqPCRs
– Perform immunofluorescence and immunohistochemistry immunostaining, and analyze them by microscopy
– Use an ex vivo preclinical model of glioblastoma (tumoroids)
– Test the therapeutic potential of new molecules (SiRNA) on these models
– Process the data: analyze, interpret and validate the results
– Apply the domain’s hygiene and safety rules (human samples)
Required profile
The candidate should have knowledge of Cancer Biology.
He / she should have strong skills in cell culture and molecular biology.
Knowledge of stem cells and gliomas would be a plus.
Hierarchical positioning
Under the responsibility of Dr Emeline Tabouret MD PhD, responsible for this research project within the GlioME team (INP, CNRS 7051) and neuro-oncologist at the Assistance-Publique des Hôpitaux de Marseille.
To submit your application
Please send your application (CV + cover letter + 1 to 2 letters of recommendation)
To: Dr Emeline Tabouret [email protected]
Pr Dominique FIGARELLA-BRANGER [email protected]
Cc: Carole COLIN [email protected]
Job offer_inge gliome dec 2021 (002)
–
